Sector
PharmaceuticalsOpen
₹4.54Prev. Close
₹4.33Turnover(Lac.)
₹0.06Day's High
₹4.54Day's Low
₹4.5452 Week's High
₹052 Week's Low
₹0Book Value
₹-5.13Face Value
₹10Mkt Cap (₹ Cr.)
9.23P/E
0EPS
0Divi. Yield
0No Record Found
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Equity Capital | 19.74 | 19.74 | 19.74 | 19.74 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -30.76 | -30.75 | -30.65 | -30.24 |
Net Worth | -11.02 | -11.01 | -10.91 | -10.5 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
yoy growth (%) | 0 | 0 | 0 | 0 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | 0 | 0 | -0.03 | -0.03 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 0 | -0.09 | -0.08 | -0.25 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | -0.03 | -0.01 | -0.01 | 0.01 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | 0 | 0 |
Op profit growth | -96.06 | 12.55 | -66.14 | 4,126.06 |
EBIT growth | -96.06 | 12.55 | -66.14 | -921.77 |
Net profit growth | -95.93 | 12.57 | -66.27 | -1,344.04 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,672.85 | 93.87 | 4,01,372.75 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,931.8 | 83.3 | 1,84,017.51 | 667 | 0.43 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,488.15 | 24.97 | 1,20,199.04 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,323.45 | 59.44 | 1,12,475.6 | 474 | 0.18 | 2,385 | 224.34 |
Dr Reddys Laboratories Ltd DRREDDY | 1,283.9 | 19.91 | 1,07,151.95 | 1,200.7 | 0.62 | 5,546.3 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
Dushyant Kumar Singh
Company Secretary
N S Parameshwaran
Independent Director
Hawa Singh Chahar
Director & Chief Executive Off
Dhruv Singh
Upper Kesalton,
Tallital,
Uttar Pradesh - 263001
Tel: 91-98718 62796
Website: http://www.mescopharma.com
Email: nsparameswaran@mescosteel.com; mescogroup@rediffma
D-153/A 1st Flr,
Okhla Industrial Are, Phase-I,
New Delhi-110020
Tel: 91-11-26812682
Website: www.skylinerta.com
Email: admin@skylinerta.com/virenr@skylinerta.com
Summary
Mesco Pharmaceuticals started commercial operations in Jun.91 by venturing into seed-marketing of bulk drugs and formulations with the objective of later establishing facilities for manufacture of bul...
Read More
Reports by Mesco Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.